Department of Breast Surgery, The Affiliated Calmette Hospital of Kunming Medical University, No. 1228, Beijing Road, Panlong District, Kunming, 650224, Yunnan, China.
Department of Hepatopancreatobiliary Surgery, The Affiliated Calmette Hospital of Kunming Medical University, No. 1228, Beijing Road, Panlong District, Kunming, 650224, Yunnan, China.
World J Surg Oncol. 2022 Apr 27;20(1):134. doi: 10.1186/s12957-022-02598-y.
To describe the clinical outcome and physical condition of patients with locally advanced breast cancer (LABC) who received neoadjuvant chemotherapy followed by mastectomy and latissimus dorsi myocutaneous flap repair.
A retrospective review of 142 patients with locally advanced breast cancer was selected from 1156 breast cancer patients in the South and North areas of The Affiliated Calmette Hospital of Kunming Medical University between May 2008 and December 2018.
All participants (n = 142) were women aged 40-55 years (average age 47.35 ± 0.43 years) who received neoadjuvant chemotherapy followed by mastectomy and latissimus dorsi flap repair. The median follow-up period was 16 months (range 12-24 months). For stage of disease, there were 19 cases (13%) in stage IIB, 31 cases (22%) in stage IIIA, 39 cases (28%) in stage IIIB, and 53 cases (37%) in stage IIIC, which were statistically significant with the physical condition of patients (≤ 0.001). Neoadjuvant chemotherapy was administered to shrink the tumors, and an average tumor size decrease from 10.05 ± 1.59 cm × (8.07 ± 1.54) cm to 6.11 ± 1.72 cm × (3.91 ± 1.52) cm (P < 0.001) was considered statistically significant. A t test was used for the ECOG score statistics, and the results showed that the scores were statistically significant (≤ 0.001) before and after neoadjuvant chemotherapy and after surgery.
Neoadjuvant chemotherapy is an accepted treatment option for patients with locally advanced breast cancer, and the use of a latissimus dorsi musculocutaneous flap for post-mastectomy reconstruction may improve the patients' physical condition. Our results indicated that this strategy was safe and feasible.
描述接受新辅助化疗后行乳房切除术和背阔肌肌皮瓣修复的局部晚期乳腺癌（LABC）患者的临床转归和身体状况。
从昆明医科大学附属 Calmette 医院南区和北区 2008 年 5 月至 2018 年 12 月收治的 1156 例乳腺癌患者中，选取 142 例局部晚期乳腺癌患者进行回顾性分析。
所有参与者（n=142）均为 40-55 岁女性（平均年龄 47.35±0.43 岁），均接受新辅助化疗后行乳房切除术和背阔肌肌皮瓣修复。中位随访时间为 16 个月（12-24 个月）。根据疾病分期，ⅡB 期 19 例（13%），ⅢA 期 31 例（22%），ⅢB 期 39 例（28%），ⅢC 期 53 例（37%），与患者身体状况差异有统计学意义（≤0.001）。新辅助化疗用于缩小肿瘤，平均肿瘤大小从 10.05±1.59cm×（8.07±1.54）cm 缩小至 6.11±1.72cm×（3.91±1.52）cm（P＜0.001），差异有统计学意义。ECOG 评分采用 t 检验进行统计学分析，结果显示新辅助化疗前后及手术后评分差异有统计学意义（≤0.001）。
新辅助化疗是局部晚期乳腺癌患者的一种可接受的治疗选择，背阔肌肌皮瓣用于乳房切除术后重建可能会改善患者的身体状况。我们的研究结果表明，该策略是安全可行的。
